Eli Lilly's Oral GLP-1 Pill Demonstrates Success in Phase 3 Trials

The first nonpeptide oral GLP-1 therapy, orforglipron, matches injectable drugs in weight-loss and glucose-control efficacy, with FDA filings planned for late 2025.